Calendar
event
Ex dividend date
11 Feb 2026
event_available
Last Dividend Payment
25 Feb 2026
About Kenvue Inc.
Ticker
info
KVUE
Trading on
info
NYSE
ISIN
info
US49177J1025
Industry
info
Household & Personal Products
Sector
info
Consumer Defensive
CEO
info
Kirk L. Perry
Headquarters
info
1 Kenvue Way, Summit, NJ, United States, 07901
Employees
info
21,780
Website
info
kenvue.com
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Metrics
BasicAdvanced
Market cap
info
$33.3B
P/E ratio
info
22.88
EPS
info
$0.76
Dividend Yield
info
4.67%
Beta
info
0.47
Forward P/E ratio
info
15.67
EBIDTA
info
$3.24B
Ex dividend date
info
2026-02-11
Price & volume
Market cap
info
$33.3B
Average daily volume
info
35.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.83
Dividend yield
info
4.67%
Forward dividend per share
info
$0.83
Forward dividend yield
info
4.77%
Payout ratio
info
76.76%
Valuation
P/E ratio
info
22.88
Forward P/E
info
15.67
PEG ratio
info
1.49
Trailing P/E
info
22.88
Price to sales
info
2.2
Price to book
info
3.1
Earnings
EPS
info
$0.76
EPS estimate (current quarter)
info
$0.22
EPS estimate (next quarter)
info
$0.26
EBITDA
info
$3.24B
Revenues (TTM)
info
$15.1B
Revenues per share (TTM)
info
$7.89
Technicals
Beta
info
0.47
52-week High
info
$24.13
52-week Low
info
$13.69
50-day moving average
info
$17.86
200-day moving average
info
$18.72
Short ratio
info
1.25
Short %
info
3.56%
Management effectiveness
ROE (TTM)
info
14.39%
ROA (TTM)
info
6.61%
Profit margin
info
9.72%
Gross profit margin
info
$8.83B
Operating margin
info
17.83%
Growth
Quarterly earnings growth (YoY)
info
11.20%
Quarterly revenue growth (YoY)
info
3.20%
Share stats
Outstanding Shares
info
1.92B
Float
info
1.91B
Insiders %
info
0.05%
Institutions %
info
96.20%
Analyst Insights & forecasts
info

27% Buy

73% Hold

0% Sell

Based on information from 19 analysts.

Average price target

info
$19.83
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.24
$0.23
4.35%
Q1 • 25Beat
$0.29
$0.28
3.57%
Q2 • 25Beat
$0.28
$0.26
7.69%
Q3 • 25Beat
$0.27
$0.22
22.73%
Q4 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$3.76B
$398M
10.57%
Q3 • 25
$3.78B
$330M
8.73%
Q4 • 25
0.43%
-17.09%
-17.44%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$27.2B
$16.6B
60.97%
Q3 • 25
$27.1B
$16.3B
60.24%
Q4 • 25
-0.63%
-1.82%
-1.20%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$294M
$-104M
$-110M
$196M
Q3 • 25
$854M
-
$-869M
$744M
Q4 • 25
190.48%
-
690.00%
279.59%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Kenvue Inc. share?
Collapse

Kenvue Inc. shares are currently traded for undefined per share.

How many shares does Kenvue Inc. have?
Collapse

Kenvue Inc. currently has 1.92B shares.

Does Kenvue Inc. pay dividends?
Collapse

Yes, Kenvue Inc. does pay dividends.

What is Kenvue Inc. 52 week high?
Collapse

Kenvue Inc. 52 week high is $24.13.

What is Kenvue Inc. 52 week low?
Collapse

Kenvue Inc. 52 week low is $13.69.

What is the 200-day moving average of Kenvue Inc.?
Collapse

Kenvue Inc. 200-day moving average is $18.72.

Who is Kenvue Inc. CEO?
Collapse

The CEO of Kenvue Inc. is Kirk L. Perry.

How many employees Kenvue Inc. has?
Collapse

Kenvue Inc. has 21,780 employees.

What is the market cap of Kenvue Inc.?
Collapse

The market cap of Kenvue Inc. is $33.3B.

What is the P/E of Kenvue Inc.?
Collapse

The current P/E of Kenvue Inc. is 22.88.

What is the EPS of Kenvue Inc.?
Collapse

The EPS of Kenvue Inc. is $0.76.

What is the PEG Ratio of Kenvue Inc.?
Collapse

The PEG Ratio of Kenvue Inc. is 1.49.

What do analysts say about Kenvue Inc.?
Collapse

According to the analysts Kenvue Inc. is considered a hold.